Skip to main content
Eledon Pharmaceuticals, Inc. logo

Eledon Pharmaceuticals, Inc. — Investor Relations & Filings

Ticker · ELDN ISIN · US67011N2045 LEI · 549300S17CAM13O43606 US Professional, scientific and technical activities
Open in API
Filings indexed 585 across all filing types
Latest filing 2017-07-05 Director's Dealing
Country US United States of America
Listing US ELDN

About Eledon Pharmaceuticals, Inc.

https://eledon.com/

Eledon Pharmaceuticals, Inc. is a clinical-stage biotechnology company developing immune-modulating therapies for organ transplantation and autoimmune diseases. The company's mission, "One Transplant for Life," focuses on improving transplant longevity and the quality of life for recipients. Its lead product candidate, tegoprubart, is an anti-CD40 Ligand (CD40L) antibody designed to regulate the immune system to prevent organ rejection. Eledon has completed a Phase 2 clinical trial evaluating tegoprubart in kidney transplant recipients and is advancing the compound into late-stage development. The company is also exploring tegoprubart's potential in other applications, including liver transplantation and xenotransplantation.

Recent filings

Filing Released Lang Actions
FORM 4 SUBMISSION
Director's Dealing
2017-07-05 English
Regulatory Filings 2017
Regulatory Filings
2017-06-28 English
S-3
Capital/Financing Update Classification · 95% confidence The document is a Form S-3 Registration Statement filed with the SEC, which is a registration statement under the Securities Act of 1933. It includes details about the securities being registered, the company, and the offering but does not contain financial statements or analysis typical of annual or quarterly reports. It is a regulatory filing related to capital raising and securities registration, not a financial report or earnings release. Therefore, it fits best under Capital/Financing Update (CAP). The document length is substantial and contains detailed registration information, not just an announcement or notice, so it is not RPA or RNS. Hence, the classification is CAP with high confidence.
2017-06-23 English
8-A12B/A
Regulatory Filings Classification · 100% confidence The document is a Form 8-A/A filed with the SEC, which is used for the registration of certain classes of securities pursuant to Section 12(b) or 12(g) of the Securities Exchange Act of 1934. It includes details about the registration of common stock on NASDAQ, a reverse stock split, and a name change. This is a regulatory filing related to securities registration and amendments, not a financial report, earnings release, or management discussion. The document is relatively short (4634 characters) and contains legal and regulatory information about securities registration. Therefore, it fits best under Regulatory Filings (RNS).
2017-06-23 English
FORM 8-K
Board/Management Information Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events that shareholders should know about. The content specifically details changes in compensation for the CEO and CFO, including salary increases and bonus payouts. This fits the category of announcements related to changes in senior management or board-related information. There is no financial statement or detailed financial report included, so it is not an Annual Report, Interim Report, or Earnings Release. The document is not a proxy solicitation, voting results, or a regulatory filing of a different nature. Therefore, the best classification is Board/Management Information (MANG). The document length is under 5,000 characters and contains substantive information about management compensation changes, not just an announcement of a report, so it is not RPA or RNS.
2017-05-31 English
FORM 4 SUBMISSION
Director's Dealing
2017-05-26 English

Browse filings by year

18 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.